A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Not Recruiting

Trial ID: NCT00631462


The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Official Title

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis

Stanford Investigator(s)

Jason Gotlib

Professor of Medicine (Hematology)


Inclusion Criteria:

   - Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential

   - At least 18 years of age.

   - ECOG PS 0, 1, or 2.

Exclusion Criteria:

   - Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy,
   corticosteroids, or growth factor treatment within 14 days prior to initiation of
   study drug.

   - Major surgery or radiation therapy within 28 days prior to initiation of study drug.


drug: TG101348

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Linder

New Trial Alerts